Natriuretic peptide receptors and neutral endopeptidase in mediating the renal actions of a new therapeutic synthetic natriuretic peptide dendroaspis natriuretic peptide
Horng H. Chen, MB, BCh*,*,
John G. Lainchbury, MD* and
John C. Burnett, Jr, MD*
* Cardiorenal Research Laboratory, Division of Cardiovascular Diseases and Department of Physiology, Mayo Clinic and Foundation, Rochester, Minnesota, USA
View larger version (14K):
[in a new window]
|
Figure 1 Amino acid sequence and structure of natriuretic peptides. ANP = atrial natriuretic peptide; BNP = brain natriuretic peptide; CNP = C-type natriuretic peptide; DNP = Dendroaspsis natriuretic peptide.
|
|
View larger version (36K):
[in a new window]
|
Figure 2 Urinary sodium excretion (UNaV), distal tubular fractional reabsorption of sodium (DFNaR), glomerular filtration rate (GFR), and renal blood flow (RBF) at baseline (open bars), with intra-renal Dendroaspis natriuretic peptide (DNP) infusion alone (hatched bars) and 30, 60, 90, and 120 min after intravenous bolus administration of HS-142-1 (HS) (solid bars) in addition to continuous intra-renal infusion of DNP. *p < 0.05 versus baseline; p < 0.05 versus intra-renal DNP alone.
|
|
View larger version (27K):
[in a new window]
|
Figure 3 Plasma cGMP and urinary cGMP excretion (UcGMPV) at baseline (open bars), with intra-renal Dendroaspis natriuretic peptide (DNP) infusion alone (hatched bars) and 30, 60, 90, and 120 min after intravenous bolus administration of HS-142-1 (HS) (solid bars) in addition to continuous intra-renal infusion of DNP. *p < 0.05 versus baseline; p < 0.05 versus intra-renal DNP alone.
|
|
|
